Neurocrine Biosciences (NASDAQ:NBIX) Price Target Increased to $216.00 by Analysts at Oppenheimer

Neurocrine Biosciences (NASDAQ:NBIX – Free Report) had its target price increased by Oppenheimer from $200.00 to $216.00 in a research report report published on Thursday morning, Benzinga reports. The firm currently has an outperform rating on the stock. Several other equities analysts have also weighed in on the company. Wells Fargo & Company upgraded Neurocrine […]

Related Keywords

Mediolanum ,Lombardia ,Italy ,United States ,Davidw Boyer ,Eric Benevich ,Neurocrine Biosciences ,Citigroup ,Nasdaq ,Goldman Sachs Group ,Central Pacific Bank Trust Division ,Fidelis Capital Partners ,Wells Fargo Company ,Mediolanum International Funds Ltd ,Daiwa Securities Group Inc ,Neurocrine Biosciences Company Profile ,Securities Exchange Commission ,Neurocrine Biosciences Inc ,Free Report ,Moderate Buy ,Get Free Report ,Exchange Commission ,International Funds Ltd ,Management Fondsmaeglerselskab ,Pacific Bank Trust Division ,Securities Group ,Neurocrine Biosciences Daily ,Nasdaq Nbix ,Nbix ,Medical ,64125c10 ,Boost Price Target ,Oppenheimer Holdings Inc ,